SG11201407703QA - Methanethione compounds having antiviral activity - Google Patents
Methanethione compounds having antiviral activityInfo
- Publication number
- SG11201407703QA SG11201407703QA SG11201407703QA SG11201407703QA SG11201407703QA SG 11201407703Q A SG11201407703Q A SG 11201407703QA SG 11201407703Q A SG11201407703Q A SG 11201407703QA SG 11201407703Q A SG11201407703Q A SG 11201407703QA SG 11201407703Q A SG11201407703Q A SG 11201407703QA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- compound
- formula
- stockholm
- methanethione
- Prior art date
Links
- DBTDEFJAFBUGPP-UHFFFAOYSA-N Methanethial Chemical class S=C DBTDEFJAFBUGPP-UHFFFAOYSA-N 0.000 title abstract 2
- 230000000840 anti-viral effect Effects 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 4
- 239000003443 antiviral agent Substances 0.000 abstract 1
- 206010022000 influenza Diseases 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
- C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 21 November 2013 (21.11.2013) WIPOIPCT (10) International Publication Number WO 2013/171334 A1 (51) International Patent Classification: C07D 249/10 (2006.01) A61K31/44 (2006.01) C07D 261/18 (2006.01) A61P 31/16 (2006.01) (21) International Application Number: (22) International Filing Date: (25) Filing Language: (26) Publication Language: (30) Priority Data: 61/648,700 61/659,516 61/666,286 61/774,991 PCT/EP2013/060266 17 May 2013 (17.05.2013) English English US US us us 18 May 2012 (18.05.2012) 14 June 2012 (14.06.2012) 29 June 2012 (29.06.2012) 8 March 2013 (08.03.2013) (71) Applicant: VIRONOVA AB [SE/SE]; Gavlegatan 22, S- 11330 Stockholm (SE). (72) Inventors: HOMMAN, Mohammed; Serenadvagen 1 A 8tr, S-13153 Nacka (SE). KINGI, Ngarita; Gardstigen 16, S-12552 Alvsjo (SE). BERGMAN, Jan; Lekgrand 5, S- 163 46 Spanga (SE). ENGQVIST, Robert; Engelbergsva- gen 69, S-144 62 Ronninge (SE). (74) Agent: BRANN AB; P.O. Box 12246, S-10226 Stockholm (SE). (81) Designated States (unless otherwise indicated, for every kind of national protection available)'. AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available)'. ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: — of inventorship (Rule 4.17(iv)) Published: — with international search report (Art. 21(3)) (54) Title: METHANETHIONE COMPOUNDS HAVING ANTIVIRAL ACTIVITY (R )n 1 i-H (57) Abstract: A compound of formula (I), The compound is useful as an antiviral agent, in particular for the treatment of influenza. O A method for preparing the compound of formula (I) and a composition comprising the compound of formula (I).
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261648700P | 2012-05-18 | 2012-05-18 | |
| US201261659516P | 2012-06-14 | 2012-06-14 | |
| US201261666286P | 2012-06-29 | 2012-06-29 | |
| US201361774991P | 2013-03-08 | 2013-03-08 | |
| PCT/EP2013/060266 WO2013171334A1 (en) | 2012-05-18 | 2013-05-17 | Methanethione compounds having antiviral activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201407703QA true SG11201407703QA (en) | 2015-01-29 |
Family
ID=48444409
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201407703QA SG11201407703QA (en) | 2012-05-18 | 2013-05-17 | Methanethione compounds having antiviral activity |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US9359310B2 (en) |
| EP (1) | EP2870141B1 (en) |
| JP (2) | JP6484168B2 (en) |
| KR (1) | KR102092207B1 (en) |
| CN (1) | CN104540810B (en) |
| AU (1) | AU2013261735B2 (en) |
| BR (1) | BR112014028632B1 (en) |
| CA (1) | CA2879816C (en) |
| CL (1) | CL2014003116A1 (en) |
| DK (1) | DK2870141T3 (en) |
| EA (1) | EA029044B1 (en) |
| ES (1) | ES2657942T3 (en) |
| IL (1) | IL235742A0 (en) |
| IN (1) | IN2014DN10658A (en) |
| MX (1) | MX356846B (en) |
| MY (1) | MY169094A (en) |
| NZ (1) | NZ702073A (en) |
| SG (1) | SG11201407703QA (en) |
| WO (1) | WO2013171334A1 (en) |
| ZA (1) | ZA201409220B (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112014028632B1 (en) * | 2012-05-18 | 2020-01-28 | Vironova Ab | compound, pharmaceutical composition, and method for preparing a compound |
| CN107056762B (en) * | 2016-12-22 | 2020-08-28 | 四川百利药业有限责任公司 | Bis-carbonyl analogues for use against influenza virus |
| WO2021204923A1 (en) | 2020-04-09 | 2021-10-14 | Vironova Medical Ab | Antiviral agents |
| WO2021204924A1 (en) | 2020-04-09 | 2021-10-14 | Vironova Medical Ab | Compounds for use in the treatment of hypercytokinemia |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6642390B2 (en) | 2001-07-11 | 2003-11-04 | Lexicon Pharmaceuticals, Inc. | One step synthesis of 1,2,3-triazole carboxylic acids |
| WO2004078732A1 (en) * | 2003-01-28 | 2004-09-16 | Aventis Pharma S.A. | N-aryl heteroaromatic products, compositions containing same and use thereof |
| WO2009131957A2 (en) | 2008-04-21 | 2009-10-29 | Institute For Oneworld Health | Compounds, compositions and methods comprising oxadiazole derivatives |
| AU2010281265A1 (en) * | 2009-08-05 | 2012-03-22 | Versitech Limited | Antiviral compounds and methods of making and using thereof |
| EA201390476A1 (en) | 2010-09-28 | 2013-08-30 | Бристол-Майерс Сквибб Компани | NEW PIPERAZIN ANALOGUES WITH SUBSTITUTED HETEROARRY GROUPS AS ANTI-VIRUS MEANS OF WIDE APPLICATION AGAINST FLU |
| EP2484655A1 (en) | 2011-02-04 | 2012-08-08 | Vironova AB | A thionation process and a thionating agent |
| BR112014028632B1 (en) * | 2012-05-18 | 2020-01-28 | Vironova Ab | compound, pharmaceutical composition, and method for preparing a compound |
| JP6762767B2 (en) * | 2016-06-01 | 2020-09-30 | キヤノン株式会社 | Image sensor, image sensor, and image signal processing method |
-
2013
- 2013-05-17 BR BR112014028632A patent/BR112014028632B1/en not_active IP Right Cessation
- 2013-05-17 KR KR1020147035090A patent/KR102092207B1/en not_active Expired - Fee Related
- 2013-05-17 WO PCT/EP2013/060266 patent/WO2013171334A1/en not_active Ceased
- 2013-05-17 EA EA201401277A patent/EA029044B1/en not_active IP Right Cessation
- 2013-05-17 CN CN201380038170.2A patent/CN104540810B/en not_active Expired - Fee Related
- 2013-05-17 ES ES13722781.5T patent/ES2657942T3/en active Active
- 2013-05-17 SG SG11201407703QA patent/SG11201407703QA/en unknown
- 2013-05-17 CA CA2879816A patent/CA2879816C/en active Active
- 2013-05-17 EP EP13722781.5A patent/EP2870141B1/en active Active
- 2013-05-17 NZ NZ702073A patent/NZ702073A/en not_active IP Right Cessation
- 2013-05-17 JP JP2015512081A patent/JP6484168B2/en not_active Expired - Fee Related
- 2013-05-17 IN IN10658DEN2014 patent/IN2014DN10658A/en unknown
- 2013-05-17 AU AU2013261735A patent/AU2013261735B2/en not_active Ceased
- 2013-05-17 MX MX2014014007A patent/MX356846B/en active IP Right Grant
- 2013-05-17 US US14/401,545 patent/US9359310B2/en not_active Expired - Fee Related
- 2013-05-17 DK DK13722781.5T patent/DK2870141T3/en active
- 2013-05-17 MY MYPI2014003200A patent/MY169094A/en unknown
-
2014
- 2014-11-17 CL CL2014003116A patent/CL2014003116A1/en unknown
- 2014-11-17 IL IL235742A patent/IL235742A0/en active IP Right Grant
- 2014-12-15 ZA ZA2014/09220A patent/ZA201409220B/en unknown
-
2017
- 2017-11-09 JP JP2017216649A patent/JP2018065817A/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| ES2657942T3 (en) | 2018-03-07 |
| CA2879816C (en) | 2020-07-07 |
| WO2013171334A1 (en) | 2013-11-21 |
| CN104540810A (en) | 2015-04-22 |
| JP6484168B2 (en) | 2019-03-13 |
| DK2870141T3 (en) | 2018-01-29 |
| EA029044B1 (en) | 2018-02-28 |
| US9359310B2 (en) | 2016-06-07 |
| MY169094A (en) | 2019-02-18 |
| CA2879816A1 (en) | 2013-11-21 |
| CL2014003116A1 (en) | 2015-08-07 |
| MX356846B (en) | 2018-06-18 |
| KR20150012289A (en) | 2015-02-03 |
| KR102092207B1 (en) | 2020-03-23 |
| BR112014028632B1 (en) | 2020-01-28 |
| MX2014014007A (en) | 2015-05-11 |
| US20150133468A1 (en) | 2015-05-14 |
| HK1210165A1 (en) | 2016-04-15 |
| JP2015517516A (en) | 2015-06-22 |
| NZ702073A (en) | 2017-07-28 |
| IN2014DN10658A (en) | 2015-08-28 |
| CN104540810B (en) | 2017-01-18 |
| AU2013261735A1 (en) | 2015-01-22 |
| EP2870141B1 (en) | 2017-11-22 |
| EA201401277A1 (en) | 2015-04-30 |
| BR112014028632A2 (en) | 2017-06-27 |
| BR112014028632A8 (en) | 2018-04-03 |
| EP2870141A1 (en) | 2015-05-13 |
| IL235742A0 (en) | 2015-02-01 |
| AU2013261735B2 (en) | 2017-07-20 |
| ZA201409220B (en) | 2016-08-31 |
| JP2018065817A (en) | 2018-04-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201407228PA (en) | N-aryltriazole compounds as lpar antagonists | |
| SG11201407037UA (en) | Catechol o-methyltransferase activity inhibiting compounds | |
| SG11201407534PA (en) | New diazaspirocycloalkane and azaspirocycloalkane | |
| SG11201408094YA (en) | Neprilysin inhibitors | |
| SG11201407220YA (en) | N-alkyltriazole compounds as lpar antagonists | |
| SG11201907650RA (en) | Personal therapy and exercise monitoring and oversight devices, systems, and related methods | |
| SG11201408261UA (en) | Syringe | |
| SG11201407200TA (en) | Liquid formulation | |
| SG11201408237YA (en) | Compound as wnt signaling inhibitor, composition, and use thereof | |
| SG11201408659UA (en) | Load carrying platform shuttle | |
| SG11201408303WA (en) | Adhesive compositions of propylene-based and ethylene-based polymers | |
| SG11201408641UA (en) | Phenoxyethyl piperidine compounds | |
| SG11201908640TA (en) | Pyrrolidinones and a process to prepare them | |
| SG11201408629QA (en) | Dimethyl-benzoic acid compounds | |
| SG11201407546QA (en) | Novel ring-substituted n-pyridinyl amides as kinase inhibitors | |
| SG11201407536UA (en) | Topical pharmaceutical compositions comprising terbinafine and urea | |
| SG11201407189XA (en) | C-17 bicyclic amines of triterpenoids with hiv maturation inhibitory activity | |
| SG11201406787TA (en) | Rnai-based therapies for cardiomyopathies, muscular dystrophies and laminopathies | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201407229UA (en) | Substituted pyrazole compounds as lpar antagonists | |
| SG11201408685WA (en) | Antibacterial microelement chelates and the use thereof in animal feeds | |
| SG11201407575PA (en) | 5-amino[1,4]thiazines as bace 1 inhibitors | |
| SG11201901438VA (en) | Solid forms of cenicriviroc mesylate and processes of making solid forms of cenicriviroc mesylate | |
| SG11201407345QA (en) | Pyrazole compounds as sglt1 inhibitors | |
| SG11201407184PA (en) | Process for preparation of optically pure and optionally substituted 2- (1 -hydroxy- alkyl) - chromen - 4 - one derivatives and their use in preparing pharmaceuticals |